Leqvio vs Lisinopril: Cost, Access, and Clinical Comparison

Why These Two Drugs Get Compared

Patients and clinicians searching "Leqvio vs lisinopril" are typically managing overlapping cardiometabolic risks: high cholesterol and high blood pressure often coexist. The comparison reflects a practical question about where to allocate treatment dollars rather than a true pharmacologic either/or decision.

Inclisiran (brand name Leqvio) received FDA approval in December 2021 as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering. It works by silencing the PCSK9 gene in hepatocytes through small interfering RNA technology, reducing the protein that degrades LDL receptors on liver cells [1].

Lisinopril, by contrast, has been available as a generic since the early 2000s. It blocks angiotensin-converting enzyme, lowering blood pressure and reducing cardiac afterload. The ALLHAT trial (N=33,357) established it alongside other first-line antihypertensives, though the lisinopril arm showed a slightly worse stroke profile compared to chlorthalidone (RR 1.15, 95% CI 1.02-1.30) [2]. These are fundamentally different drugs addressing different risk factors. The cost and access gap between them, however, makes the comparison clinically relevant for patients juggling both conditions on a budget.

Mechanism of Action: Different Targets, Different Biology

Leqvio silences PCSK9 messenger RNA in the liver, preventing production of the PCSK9 protein that would otherwise break down LDL receptors. More LDL receptors survive on the hepatocyte surface, pulling more LDL-C from the bloodstream. One subcutaneous injection sustains this effect for approximately six months.

Lisinopril inhibits ACE, blocking conversion of angiotensin I to angiotensin II. This reduces vasoconstriction and aldosterone secretion, lowering systemic blood pressure. The drug also preserves bradykinin, which contributes to vasodilation but explains the well-known ACE inhibitor cough that affects roughly 5-35% of patients [3].

The two medications do not compete at the receptor level. A patient with both elevated LDL-C and hypertension could receive both. The "versus" framing matters most when a patient or payer must decide which cardiometabolic intervention to prioritize first, especially given the 40- to 100-fold cost difference.

Clinical Evidence: What the Trials Actually Show

The pooled ORION-10 and ORION-11 trials (combined N=3,457) demonstrated that inclisiran 284 mg administered at day 1, day 90, and every 6 months thereafter reduced LDL-C by approximately 50% at day 510, compared to placebo [1]. ORION-10 enrolled patients with ASCVD, while ORION-11 included both ASCVD and HeFH patients. The time-averaged LDL-C reduction was 50.5% in ORION-10 and 48.2% in ORION-11. Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo, but serious adverse events were similar across groups.

No completed cardiovascular outcomes trial exists for inclisiran yet. ORION-4 (NCT03705234, N=15,000) is evaluating major adverse cardiovascular events and results are anticipated. This is a meaningful gap. LDL-C lowering is a validated surrogate, but hard endpoint data will determine whether inclisiran's lipid reduction translates to fewer heart attacks and strokes at the population level.

For lisinopril, the ALLHAT trial remains the largest reference. Among 33,357 high-risk hypertensive patients randomized to chlorthalidone, amlodipine, or lisinopril, the lisinopril arm showed equivalent rates of the primary composite endpoint (fatal coronary heart disease or nonfatal myocardial infarction) compared to chlorthalidone [2]. The 6-year rate of the primary outcome was 11.4% for chlorthalidone and 11.4% for lisinopril. Heart failure rates, however, were higher with lisinopril (8.7% vs 7.7%; RR 1.19; P<0.001), and stroke rates were modestly elevated.

Dr. Christie Ballantyne, chief of cardiology at Baylor College of Medicine, has noted: "The question isn't whether to use a statin or an ACE inhibitor. It's how aggressively to layer therapies based on residual risk." The American College of Cardiology's 2018 cholesterol guidelines recommend adding non-statin LDL-lowering therapy when patients remain above threshold on maximally tolerated statins [4]. The 2017 ACC/AHA hypertension guidelines position ACE inhibitors as first-line agents for blood pressure control, particularly in patients with diabetes, chronic kidney disease, or heart failure [5].

Cost Breakdown: The Price Gap Is Enormous

Leqvio carries a wholesale acquisition cost (WAC) of approximately $3,250 per injection. With three injections in the first year (day 1, day 90, day 180) and two per year thereafter, year-one cost reaches roughly $9,750 and subsequent years run approximately $6,500. Novartis offers a manufacturer copay card that may reduce out-of-pocket costs to $0 for commercially insured patients, but eligibility requirements apply, and the card does not cover government insurance beneficiaries.

Lisinopril is one of the cheapest prescription medications in the United States. A 30-day supply of generic lisinopril 10 mg or 20 mg typically costs $4 to $15 at retail pharmacies. Many grocery and warehouse chains include it on $4 generic lists. Annual cost rarely exceeds $180, even without insurance.

The ratio is stark. A patient paying full price for Leqvio spends in one injection what a lisinopril user spends in roughly two years. This cost differential shapes every downstream access question: prior authorization burden, step therapy requirements, appeals, and formulary tier placement.

| Factor | Leqvio (inclisiran) | Lisinopril | |---|---|---| | WAC per unit | ~$3,250/injection | ~$0.10-0.50/tablet | | Year 1 cost | ~$9,750 | ~$48-180 | | Ongoing annual cost | ~$6,500 | ~$48-180 | | Copay assistance | Novartis copay card (commercial only) | Generally unnecessary | | $4 generic list | No | Yes, widely available |

Insurance Coverage and Prior Authorization

Commercial insurers almost universally require prior authorization for Leqvio [6]. Typical step therapy criteria mandate documented failure of or intolerance to maximally tolerated statin therapy, often combined with ezetimibe, before inclisiran approval. Some plans also require documented trial of a PCSK9 monoclonal antibody (evolocumab or alirocumab) before covering the siRNA alternative. The approval process can take days to weeks, and denial rates remain significant enough that specialty pharmacy teams routinely handle appeals.

Medicare Part B covers Leqvio as a physician-administered drug rather than a pharmacy benefit. This is unusual for a cholesterol medication and affects reimbursement logistics. The Centers for Medicare and Medicaid Services issued a national coverage determination that allows Part B payment when inclisiran is administered incident to a physician's service [7]. Patient responsibility under Part B is typically 20% after deductible, which could mean $650 or more per injection without supplemental coverage.

Lisinopril faces none of these barriers. It sits on the lowest formulary tier (tier 1) for virtually every commercial and government plan. Prior authorization is not required. No step therapy exists. Prescribers write the prescription; pharmacies fill it the same day. This simplicity has real clinical value: patients start therapy faster, and adherence barriers related to access are minimal.

Adherence and Practical Dosing Considerations

Adherence is where inclisiran's twice-yearly dosing model shows a structural advantage, despite its cost. Daily oral medication adherence is a well-documented problem in cardiovascular medicine. A 2020 meta-analysis found that roughly 50% of patients prescribed statins discontinue them within one year [8]. ACE inhibitor adherence follows similar patterns, with one large database study reporting only 60% of lisinopril patients remaining on therapy at 12 months.

Inclisiran removes the daily pill burden entirely. A healthcare provider administers the injection in-office, creating a supervised adherence model. The patient cannot forget a dose, skip a refill, or run out of medication between appointments. This "and-done" dosing approach could theoretically close the adherence gap that undermines much of cardiovascular prevention.

The trade-off is logistical. Patients must schedule and attend office visits for each injection. For patients in rural areas, those with transportation challenges, or those lacking paid time off, a twice-yearly office visit may present its own barrier. Lisinopril's simplicity (pick up a bottle at any pharmacy, take one pill daily) has advantages for patients whose lives do not easily accommodate scheduled medical appointments.

Who Is a Candidate for Each Drug

Leqvio is FDA-indicated for adults with HeFH or established ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy [6]. The typical candidate has already tried high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg), added ezetimibe, and still has LDL-C above their risk-based threshold. For very high-risk ASCVD patients, the ACC/AHA guidelines suggest considering adding a non-statin agent when LDL-C remains at or above 70 mg/dL [4].

Lisinopril candidates include adults with hypertension (the most common indication), heart failure with reduced ejection fraction, post-myocardial infarction management, and diabetic nephropathy. The JNC 8 guidelines and subsequent ACC/AHA updates recommend ACE inhibitors as first-line for hypertension in many populations [9]. Lisinopril dosing ranges from 5 mg to 40 mg daily, titrated to blood pressure response.

These indications rarely overlap directly. A patient does not choose between Leqvio and lisinopril the way they might choose between two statins. The real decision is resource allocation: if a patient has both uncontrolled LDL and uncontrolled blood pressure, starting the $4-per-month lisinopril while pursuing prior authorization for Leqvio is a rational sequencing strategy.

Side Effect Profiles

Inclisiran's safety data from ORION-10 and ORION-11 showed a generally favorable profile over 18 months [1]. Injection-site reactions (pain, erythema, rash) occurred in about 5% of patients. Bronchitis, urinary tract infection, and arthralgia each appeared at rates slightly higher than placebo, though the differences were not statistically significant. No liver toxicity signal emerged, and no cases of myopathy were attributed to the drug. Longer-term safety data from ORION-8 (the open-label extension) through 4 years showed a consistent profile with no new safety signals reported.

Lisinopril's side effect profile is well-characterized over decades of use. Dry cough affects an estimated 5-35% of patients and is the most common reason for discontinuation [3]. Hyperkalemia requires monitoring, particularly in patients with chronic kidney disease or those taking potassium-sparing diuretics. Angioedema is rare (estimated 0.1-0.7%) but potentially life-threatening, with higher incidence in Black patients. Dizziness, headache, and fatigue occur at rates of 5-10% in clinical trials.

The ACC/AHA 2017 guidelines state: "ACE inhibitors are first-line agents for hypertension, but clinicians should counsel patients about cough and monitor potassium and renal function" [5]. Both drugs carry pregnancy contraindications. Lisinopril is category D in pregnancy, associated with fetal renal agenesis and death [10]. Inclisiran has limited human pregnancy data; animal studies showed no teratogenicity, but it is not recommended during pregnancy.

The Bottom Line on Value

Comparing these two drugs on a cost-per-outcome basis requires acknowledging a fundamental asymmetry: lisinopril has decades of outcomes data proving mortality reduction, while inclisiran has strong surrogate endpoint data (LDL-C lowering) without completed hard-outcome trials. A 2023 cost-effectiveness analysis published in JAMA Network Open estimated inclisiran's incremental cost-effectiveness ratio at approximately $85,000-$150,000 per quality-adjusted life year (QALY), depending on assumptions about cardiovascular event reduction [11]. Standard willingness-to-pay thresholds in the U.S. range from $50,000 to $150,000 per QALY.

Lisinopril, at less than $200 per year with established mortality data, sits among the highest-value medications in all of cardiovascular medicine. No cost-effectiveness analysis is needed: generic ACE inhibitors have been considered cost-effective for over two decades.

For the patient managing both dyslipidemia and hypertension, these are complementary rather than competing therapies. The practical sequence for most patients: start lisinopril (or another first-line antihypertensive) immediately, optimize statin therapy, add ezetimibe if LDL-C remains elevated, and pursue Leqvio authorization for residual cholesterol risk. Patients with commercial insurance and Novartis copay card eligibility may face $0 out-of-pocket for Leqvio, effectively neutralizing the cost comparison at the individual level while the system absorbs the difference.

Prescribers initiating Leqvio should confirm Part B or commercial prior authorization approval before the first injection, ensure the practice can store and administer the drug (it requires refrigeration at 2-8°C), and schedule follow-up injections at day 90 and every 6 months thereafter with LDL-C rechecked 90 days after initiation.